dc.contributor.author | Díaz-García, Diana | |
dc.contributor.author | Montalbán-Hernández, Karla | |
dc.contributor.author | Mena-Palomo, Irene | |
dc.contributor.author | Achimas-Cadariu, Patriciu | |
dc.contributor.author | Rodriguez-Dieguez, Antonio | |
dc.contributor.author | López-Collazo, Eduardo | |
dc.contributor.author | Prashar, Sanjiv | |
dc.contributor.author | Ovejero, Karina | |
dc.contributor.author | Filice, Marco | |
dc.contributor.author | Fischer-Fodor, Eva | |
dc.contributor.author | Gómez-Ruiz, Santiago | |
dc.date.accessioned | 2020-06-12T08:47:46Z | |
dc.date.available | 2020-06-12T08:47:46Z | |
dc.date.issued | 2020-06-03 | |
dc.identifier.citation | Pharmaceutics. 2020; 12(6):512 | es_ES |
dc.identifier.issn | 1999-4923 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/10370 | |
dc.description.abstract | The synthesis, characterization and cytotoxic activity against different cancer cell lines of various mesoporous silica-based materials containing folate targeting moieties and a cytotoxic fragment based on a triphenyltin(IV) derivative have been studied. Two different mesoporous nanostructured silica systems have been used: firstly, micronic silica particles of the MSU-2 type and, secondly, mesoporous silica nanoparticles (MSNs) of about 80 nm. Both series of materials have been characterized by different methods, such as powder X-ray diffraction, X-ray fluorescence, absorption spectroscopy and microscopy. In addition, these systems have been tested against four different cancer cell lines, namely, OVCAR-3, DLD-1, A2780 and A431, in order to observe if the size of the silica-based systems and the quantity of incorporated folic acid influence their cytotoxic action. The results show that the materials are more active when the quantity of folic acid is higher, especially in those cells that overexpress folate receptors such as OVCAR-3 and DLD-1. In addition, the study of the potential modulation of the soluble folate receptor alpha (FOLR1) by treatment with the synthesized materials has been carried out using OVCAR-3, DLD-1, A2780 and A431 tumour cell lines. The results show that a relatively high concentration of folic acid functionalization of the nanostructured silica together with the incorporation of the cytotoxic tin fragment leads to an increase in the quantity of the soluble FOLR1 secreted by the tumour cells. In addition, the studies reported here show that this increase of the soluble FOLR1 occurs presumably by cutting the glycosyl-phosphatidylinositol anchor of membrane FR-α and by the release of intracellular FR-α. This study validates the potential use of a combination of mesoporous silica materials co-functionalized with folate targeting molecules and an organotin(IV) drug as a strategy for the therapeutic treatment of several cancer cells overexpressing folate receptors. | es_ES |
dc.description.sponsorship | We would like to thank Ministerio de Ciencia, Innovación y Universidades of Spain (current Ministerio de Ciencia e Innovación of Spain and Ministry of Research and Innovation, CNCS–UEFISCDI (Romania). We would also like to thank Dirección General de Investigación e Innovación, Consejería de Educación e Investigación de la Comunidad de Madrid (Spain) for the predoctoral grant PEJD‐2017‐PRE/BMD‐3512 (I.M.‐P.) and the Escuela Internacional de Doctorado of the Universidad Rey Juan Carlos for mobility grant (D.D.‐G.). M.F. and K.O.P would like to thank the Comunidad Autónoma de Madrid for research project no. 2017‐T1/BIO‐4992 (“Atracción de Talento” Action) co‐funded by Universidad Complutense de Madrid (UCM). The CNIC is supported by MINECO and the Pro‐CNIC Foundation and is a Severo Ochoa Centre of Excellence (SEV‐2015‐0505) | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Role of Folic Acid in the Therapeutic Action of Nanostructured Porous Silica Functionalized with Organotin(IV) Compounds Against Different Cancer Cell Lines. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 32503320 | es_ES |
dc.format.volume | 12 | es_ES |
dc.format.number | 6 | es_ES |
dc.identifier.doi | 10.3390/pharmaceutics12060512 | es_ES |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | |
dc.contributor.funder | Comunidad de Madrid (España) | |
dc.contributor.funder | King Juan Carlos University (España) | |
dc.contributor.funder | Fundación ProCNIC | |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/pharmaceutics12060512 | es_ES |
dc.identifier.journal | Pharmaceutics | es_ES |
dc.repisalud.orgCNIC | CNIC::Unidades técnicas::Microscopía | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SEV-2015-0505 | es_ES |
dc.rights.accessRights | open access | es_ES |